Blood test score may flag High-Risk esophageal surgery patients

NCT ID NCT07761975

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study looks at whether a simple score calculated from routine blood tests—measuring hemoglobin, albumin, lymphocytes, and platelets (the HALP score)—can help predict complications after surgery to remove esophageal cancer. Researchers will track how this score changes before and after surgery in 131 adults and see if it relates to problems like leaks, intensive care needs, or longer hospital stays. The goal is to find out if this easy-to-measure score could serve as a warning sign for patients who may need extra care during recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Perioperative HALP score assessment using routine blood tests
What this could lead to
If the HALP score proves useful, it could become a simple, low-cost tool to help doctors identify patients at higher risk of complications after esophageal cancer surgery, potentially improving recovery planning.
What could go wrong
This is a retrospective observational study, so it can only show associations, not cause and effect. The HALP score may not reliably predict outcomes in all patients or settings, and its clinical usefulness remains uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal cancer Postoperative Complications

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Basaksehir Cam and Sakura City Hospital

    Istanbul, Istanbul, 34480, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.